Nab-paclitaxel plus capecitabine as first-line treatment for patients with recurrence or metastatic biliary tract cancer

被引：0
|
作者：
Zhou, J. [1 ]
Zong, Y. [1 ]
Yuan, J. [1 ]
Peng, Z. [1 ]
Lu, M. [1 ]
Wang, X. [1 ]
Shen, L. [1 ]
机构：
[1] Beijing Canc Hosp, Dept Gastrointestinal Oncol, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.458
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
194P
引用
收藏
页码：S1315 / S1315
页数：1
相关论文
共 50 条
  • [31] Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX
    Kim, George P.
    Parisi, Monika F.
    Patel, Manish B.
    Pelletier, Corey L.
    Belk, Kathy W.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (05) : 559 - 565
  • [32] Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma, a retrospective cohort
    Wu, Hongyang
    Huang, Nana
    Zhao, Chenchen
    Hu, Xueyang
    Da, Liangshan
    Huang, Wei
    Shen, Yuanyuan
    Xiong, Fuxing
    Zhang, Congjun
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (06)
  • [33] First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population
    Hatashima, Alycia
    Arango, Matthew J.
    Reardon, Joshua
    Freeman, Tracelyn
    Williams, Terence
    McLaughlin, Eric M.
    Abushahin, Laith
    FUTURE ONCOLOGY, 2022, 18 (20) : 2521 - 2532
  • [34] Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment
    Angelica Petrillo
    Annalisa Pappalardo
    Luca Pompella
    Giuseppe Tirino
    Filomena Calabrese
    Maria Maddalena Laterza
    Marianna Caterino
    Anna Ventriglia
    Michele Orditura
    Giovanni Conzo
    Carlo Molino
    Fortunato Ciardiello
    Maria Biglietto
    Ferdinando De Vita
    Medical Oncology, 2019, 36
  • [35] First-Line Nivolumab plus Nab-Paclitaxel plus Carboplatin (C) in Advanced NSCLC
    Waterhouse, David
    Derosa, William
    Fraser, Cindy Duval
    Gutierrez, Martin
    Ko, Amy
    Ong, Teng Jin
    Pierce, Daniel
    Stergiopoulos, Sotirous
    Kelly, Karen
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S427 - S428
  • [36] Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment
    Petrillo, Angelica
    Pappalardo, Annalisa
    Pompella, Luca
    Tirino, Giuseppe
    Calabrese, Filomena
    Laterza, Maria Maddalena
    Caterino, Marianna
    Ventriglia, Anna
    Orditura, Michele
    Conzo, Giovanni
    Molino, Carlo
    Ciardiello, Fortunato
    Biglietto, Maria
    De Vita, Ferdinando
    MEDICAL ONCOLOGY, 2019, 36 (10)
  • [37] Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma
    Scheithauer, W.
    Kornek, G.
    Prager, G.
    Stranzl, N.
    Laengle, F.
    Schindl, M.
    Friedl, J.
    Klech, J.
    Roethlin, S.
    Zielinski, C.
    ANNALS OF ONCOLOGY, 2015, 26
  • [38] Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer
    Danso, M. A.
    Blum, J. L.
    Robert, N. J.
    Krekow, L.
    Rotche, R.
    Smith, D. A.
    Richards, P.
    Anderson, T.
    Richards, D. A.
    O'Shaughnessy, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] Nab-Paclitaxel/Bevacizumab/Carboplatin Chemotherapy in First-Line Triple Negative Metastatic Breast Cancer
    Hamilton, Erika
    Kimmick, Gretchen
    Hopkins, Judith
    Marcom, P. Kelly
    Rocha, Gloria
    Welch, Renee
    Broadwater, Gloria
    Blackwell, Kimberly
    CLINICAL BREAST CANCER, 2013, 13 (06) : 416 - 420
  • [40] Nab-paclitaxel plus S-1 as first-line treatment in patients with advanced pancreatic adenocarcinoma.
    Shi, Yan
    Yan, Huan
    Han, Quanli
    Nie, Yongkang
    Lv, Yao
    Wang, Zhikuan
    Dai, Guanghai
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345